Pharma giant AstraZeneca plans to invest $15 billion in R&D and manufacturing in China by 2030. This investment will enhance the company’s capabilities in cell therapy and radioconjugate discovery, benefiting oncology, haematology, and autoimmune disease areas. AstraZeneca will expand its manufacturing facilities in Wuxi, Beijing, Qingdao, and Taizhou, supporting patients in China and 70 other markets. The move aligns with Chinese President Xi Jinping’s Healthy China 2030 strategy, focusing on healthcare quality and disease prevention. AstraZeneca’s expansion in China reflects the country’s growing presence in pharma R&D, with Chinese companies contributing to 20% of drugs in global development.

Read more at Yahoo Finance: AstraZeneca pours $15bn into Chinese R&D and manufacturing operations